Latest news
Latigo Biotherapeutics, Clinical-Stage Developer of Selective Nav1.8 Non‑Opioid Pain Medicines for Acute and Chronic Pain, Files for Nasdaq Global Select Market IPO - TradingViewTradingView · Fri, 07 Aug 2026 20:39:00 GMTLatigo Biotherapeutics (LTGO) Eyes $272 Million IPO to Advance Non-Opioid Pain Medicines - SmartkarmaSmartkarma · Wed, 05 Aug 2026 02:19:02 GMTLatigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate - Genetic Engineering and Biotechnology NewsGenetic Engineering and Biotechnology News · Thu, 30 Jul 2026 13:00:14 GMTLatigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain - Business WireBusiness Wire · Wed, 29 Jul 2026 07:00:00 GMTSodium Channel Blocker Cuts Post-Surgery Pain - MedPage TodayMedPage Today · Wed, 29 Jul 2026 07:00:00 GMT